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The role of topical metronidazole in the 
management of infected wounds 
Chronic wounds represent a significant burden to both patients and the NHS. They are often associated with pain, exudate and odour, 
and can reduce patients’ mobility and lead to social 
isolation. As chronic wounds predominantly occur in 
older people, they are increasing in prevalence. The 
UK population has been steadily getting older and this 
trend is projected to continue in the future. In 2016, 
there were 11.8 million UK residents aged 65 years 
and over, representing 18% of the total population – 
25 years earlier, there were 9.1 million, accounting for 
15.8% of the population (Office for National Statistics, 
2018). The Health Survey for England shows that in 
2016, 29% of those aged 60–64 years had two or more 
chronic conditions; in those aged 75 years and over 
this figure rises to almost 50% (NHS, 2016).
Due to their longevity, chronic and non-healing 
wounds – and their associated comorbidities – are 
associated with high treatment costs (Frykberg and 
Banks, 2015). The Burden of Wounds study found 
that the NHS spent an estimated £4.5–5.1bn on 
wound treatment in 2012–13 (Guest et al, 2017).
Inflammation, infection and the formation of 
biofilms are common features of chronic wounds 
(Frykberg and Banks, 2015). It has become widely 
accepted that most chronic and hard-to-heal 
wounds contain biofilm, and that biofilm delays 
and/or prevents healing (WUWHS, 2016). See 
Figure 1 for further information on the stages of the 
Wound Infection Continuum (IWII, 2016).
The presence of infection delays healing and 
can be associated with complications including 
cellulitis, gangrene, haemorrhage and lower-
extremity amputations (Järbrink et al, 2016). 
PREVENTION AND MANAGEMENT  
OF INFECTION
Infection prevention is an important component of 
wound management. Implementing best practice 
will reduce the risk of cross contamination, 
improve patient outcomes and promote rapid 
wound healing.
The signs and symptoms of infection are listed 
in Box 1. Holistic assessment is important, and 
a careful history should be taken to identify the 
presence of any factors that increase the risk of 
infection (see Box 2). 
The presence of a deep infection or abscess can be 
masked in patients with neuropathy; however, they 
are more likely to present with flu-like symptoms or 
pain (Wounds UK, 2013). If infection is suspected, 
clinicians should examine the wound bed and 
periwound area, and document signs of redness, 
unexplained pain or malodour (Wounds UK, 2013).
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The TIMES framework, see Box 3, should 
be applied when developing a chronic wound 
management plan. Infection causes a rapid increase 
in the production of exudate, so it needs to be 
effectively managed to protect the surrounding 
skin from maceration and excoriation (Wounds 
UK, 2013). Appropriate debridement of non-viable 
or devitalised tissue reduces the bioburden and 
reduces odour (Wounds UK, 2013). Debridement 
is unlikely to remove all biofilm, therefore the 
application of topical antimicrobials as a wound-
cleansing agent with a surfactant component and/
or antimicrobial dressing, should be considered 
(Wounds UK, 2013). Systemic antibiotics may also 
be appropriate for patients at high risk of adverse 
outcomes (Wounds UK, 2013).
ANTIMICROBIALS 
Antimicrobials can have broad- or narrow-
spectrum activity against gram-positive, gram-
negative, aerobic, anaerobic, planktonic and sessile 
bacteria, fungi and spores commonly found in 
wounds. Topical formulations are useful in the 
management of infection as they provide a high 
and sustained concentration of antimicrobial at the 
site of infection and have limited or no systemic 
absorption or toxicity (Wounds UK, 2013). They 
should be used when wound bioburden appears to 
be interfering with wound healing or there is an 
increased risk of adverse outcomes (Wounds UK, 
2013). Topical antimicrobials should be selected 
based on a patient’s needs, as their modes of action, 
ability to handle exudate, pain or odour vary. Box 4 
lists the properties of an ideal topical antimicrobial 
for the treatment of chronic wounds. The effect of 
the antimicrobial selected should be monitored at 
each dressing change and assessed at 2 weeks.
Antiseptic agents, such as povidone iodine, silver 
nitrate and chlorhexidine, inhibit or kill organisms 
within a wound or on intact skin. They have a broad 
spectrum of action but are often toxic to host tissue 
(Lipsky and Hoey, 2009; IWII, 2016). They can be 
applied as topical formulations or incorporated 
into dressings. Interestingly, similar efficacy 
against common pathogens has been reported 
between honey, iodine and silver, but significant 
differences have been found when these agents 
have been included in dressings (Bradshaw, 2011). 
Consideration should therefore be given to how the 
agent is applied. 
Antibiotic agents are naturally or synthetically 
produced chemicals that kill or inhibit 
microorganisms. Antibiotics usually act on a 
specific cell target and can be used to target 
particular pathogens; however, some have broad-
spectrum activity (Lipsky and Hoey, 2009). 
They are relatively non-toxic to host tissue 
and can be used topically or systemically. The 
topical antimicrobials available in the UK for the 
management of skin infections or wounds are 
listed in Table 1. 
Antimicrobial medicines are among the most 
commonly prescribed medicines in both primary 
and secondary care. The use, misuse and overuse 
of antimicrobial medicines is considered to be a 
major driving force towards increased antimicrobial 
Figure 1: The Wound Infection Continuum (IWII, 2016)
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resistance (WHO, 2012). Although there appears 
to be a causal link between prescribed antibiotics 
and emerging resistance, there are many other 
factors that also play a role in the development 
of this resistance. While a blanket ban on 
antimicrobial use does not lend itself to practical 
treatment options, a more thoughtful approach 
to the choice and use of the available 
antimicrobial treatments can help stem the 
emergence of resistance.
TOPICAL METRONIDAZOLE
Metronidazole is an antibiotic that can be used 
to eliminate both anaerobic and aerobic bacteria. 
The gel is highly active against gram-positive and 
-negative bacteria and is the treatment of choice 
for anaerobic infections (Löfmark et al, 2010). 
A multicentre study found that the application 
of metronidazole gel significantly decreased 
the anaerobic organism colonisation of wounds 
(p=0.0006) (Findlay et al, 1996). It helps maintain 
a moist wound environment and is effective in 
tackling odour associated with infection (Kavitha et 
al, 2014). Many patients find malodour distressing; 
therefore the management of odour should be 
taken into consideration when devising a wound 
management plan.
The efficacy of topical metronidazole has 
been assessed in the treatment of a wide range of 
wounds. A literature review including 15 studies 
deduced that topical metronidazole generally 
resulted in the reduction or eradication of wound 
odour as well as a decrease in the volume of 
exudate, decrease in pain, improvement in wound 
appearance, decrease in surrounding cellulitis and 
the halting of tissue necrosis in various types of 
wound (Paul and Pieper, 2008). 
A review by Lyvers and Elliott (2015) concluded 
that metronidazole – as a cream, gel, lotion or 
intravenous solution – is useful in the treatment 
of malodorous pressure ulcers. Of the 59 cases 
included in the review, 56 reported nearly 
complete resolution of odour 2–7 days after the 
initiation of treatment. Kavitha and colleagues 
(2014) advocate the use of metronidazole in 
the treatment of diabetic foot ulcers containing 
necrotic, sloughy or granulating tissue to promote 
autolysis and odour control. Findlay et al (1996) 
reported that by day 14 of their multicentre study, 
the application of 0.75% metronidazole gel had led 
to a decrease in odour from 95% of malodorous 
benign and cancerous cutaneous ulcers. A smaller 
clinical study of 16 participants described similar 
results: at 2 weeks, all patients and investigators 
reported a significant decrease in wound odour 
following the application of 0.75% metronidazole 
gel, with 10 participants reporting no odour 
(Kalinski et al, 2005).
Findlay et al (1996) reported a significant 
reduction in the volume of discharge produced 
by wounds after 14 days of treatment with 0.75% 
metronidazole gel (p<0.0001). Kalinski and 
colleagues (2005) had similar findings, with a 
noticeable reduction in exudate from a variety 
of wounds after just two applications (48 hours) 
of topical metronidazole. This reduction in 
exudate persisted throughout the 2-week 
treatment period.
Various studies have shown that the application 
of topical metronidazole is associated with 
reduced wound pain and/or does not cause pain 
on application. For example, the patients in a 
multicentre trial reported significant reductions 
in pain after 2 weeks of treatment with 0.75% 
metronidazole gel (Finlay et al, 1996). Their 
median pain scores fell from 3.7 on day 1 to 
2.0 on day 7 and had dropped to 1.0 on day 14. 
One study found that the application of topical 
metronidazole was not associated with any pain 
(Kalinksi et al, 2005).
ANABACT: A BROAD AND COST-
EFFECTIVE TREATMENT
Anabact Gel is an aqueous gel that contains 
0.75% metronidazole. It is licensed for the 
treatment of malodorous gravitational ulcers 
(leg ulcers caused by varicose veins or resulting 
from deep vein thrombosis) and decubitus 
ulcers (otherwise known as pressure ulcers) as 
well as fungating tumours. It can therefore be 
prescribed for the management of a wide range 
of infected wounds.
The wound should be thoroughly cleaned 
before Anabact Gel is applied over all the 
affected tissue. The area should then be covered 
with a non-adherent dressing. The gel needs to 
be applied twice a day and progress reviewed at 
2 weeks.
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Box 1. Signs and symptoms of 
infection  (adapted from IWII, 
2016)
Covert ‘subtle’ signs of local infection:
 Hypergranulation
 Bleeding/friable granulation
 Epithelial bridging and pocketing 
in granulation tissue
 Wound breakdown and 
enlargement
 Delayed wound healing
 New or increasing pain
 Increasing malodour
Overt ‘classic’ signs of local infection:
Erythema
 Local warmth
 Swelling
 Purulent discharge
Delayed wound healing
New or increasing pain/tenderness
Increasing malodour
Box 2. Risk factors for 
infection (Wounds UK, 2013)
Older age 
Very young (neonatal)
Compromised immune system
Presence of certain chronic 
medical conditions (e.g. diabetes  
or circulatory disorders)
Smoking 
Excessive alcohol consumption 
Malnutrition
Medications (e.g. antibiotics, 
chemotherapy, antiplatelet drugs, 
glucocorticoid steroids, NSAIDs)
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Table 1. Properties of topical antimicrobials (Lipsky and Hoey, 2009; Dumville et al, 2017; BNF, 2018)
Product Spectrum of action Advantages Disadvantages Indications 
Bacitracin Broad-spectrum activity 
against many gram-
positive organisms
- Activity not impaired by blood, pus 
or necrotic tissue
- No cross-resistance with other 
antibiotics
- Minimal absorption
- May cause reactions (allergic, 
anaphylactic, contact dermatitis)
- Inactive against most gram-
negative organisms
- May lead to overgrowth of drug-
resistant organisms including fungi
Prevention of infection in 
minor skin wounds
Fusidic acid Staphylococcus 
aureus, streptococci, 
corynebacteria and 
clostridia
- Penetrates intact and damaged skin 
plus crust and cellular debris
- Requires 3 daily applications
- May cause hypersensitivity 
reactions
- Staphylococci resistance emerging
Staphylococcal skin infection
Metronidazole Many clinically-important 
anaerobic and some 
aerobic bacteria
- Reduces odour, exudate and 
inflammation associated with 
anaerobic and aerobic infections
Could drive resistance to systemic 
formulations
- Requires 1–2 daily applications
Malodorous fungating 
tumours, gravitational ulcers 
and decubitus ulcers*
Mupirocin Gram-positive aerobes, 
some gram-negative 
aerobes
(not Pseudomonas 
aeruginosa), 
corynebacteria,
and obligate anaerobes
- Minimal potential for allergic 
reactions
- Rare local burning and irritation
- Polyethylene glycol can accumulate 
with repeat application in large 
wounds
- Long-term use can cause 
staphylococci resistance, which is 
increasing
Bacterial skin infections, 
particularly those caused 
by gram-positive organisms 
(except pseudomonal 
infection)
Neomycin Gram-negative organisms 
(not Pseudomonas 
aeruginosa), some gram-
positive bacteria
- Requires 1–3 daily applications
- Low cost
- May enhance re-epithelialisation
- Caution required in large wounds, 
especially with azotaemia
- Hypersensitivity reactions (1–6%)
- Streptococci are generally resistant
- Inactive against obligate anaerobes
Bacterial skin infections
Retapamulin Staphylococci (not 
MRSA), streptococci and 
some anaerobes
- May be active against some 
mupirocin-resistant Streptococcus 
aureus strains
- Broader activity than mupirocin
- May cause local irritation
- Not effective against MRSA
- Expensive
Superficial bacterial skin 
infections caused by 
Staphylococcus aureus and 
Streptococcus pyogenes 
that are resistant to first-line 
topical antibacterials
Silver 
sulfadiazine
Many gram-positive and 
gram-negative organisms 
including Pseudomonas 
aeruginosa
- Requires 1–2 daily applications
- Low rate of hypersensitivity 
reaction
- Potential cross-reaction with other 
sulphonamides
- Rarely causes skin staining
Prophylaxis of infection in 
burn wounds, conservative 
management of finger-tip 
injuries, adjunct to short-
term treatment of infection 
in pressure sores and leg 
ulcers, adjunct to prophylaxis 
of infection in skin graft 
donor sites and extensive 
abrasions
*Depending upon the formulation
There are no published studies supporting the use of topical erythromycin, clindamycin, aminoglycosides other than 
neomycin, gramicidin, or tetracyclines for treating chronically infected wounds.
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Anabact Gel is up to 54% cheaper gram-for-
gram than the market leader (C&D, 2018) and 
comes in three sizes (15g, 30g and 40g), which 
reduces waste. Prescribing this product could 
therefore lead to cost savings for the NHS and 
wound care budgets.
CONCLUSION
Topical metronidazole is effective in the reduction 
of odour, exudate and pain in patients with a wide 
variety of malodorous wounds. Anabact Gel is  
the only metronidazole formulation licensed for  
the treatment of leg and pressure ulcers and is  
a cost-effective option in the management of 
wounds with a foul odour.   Wuk
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Box 3. TIMES Framework 
(Wounds UK, 2017)
T – Tissue, non-viable or 
deficient
I – Infection/inflammation
M – Moisture imbalance
E – Edge of wound non-
advancing or undermined
S – Surrounding skin
Box 4. Ideal antimicrobial 
properties (Lipsky and 
Hoey, 2009; IWII, 2016)
 Properly targeted antimicrobial 
spectrum for the particular 
type of infected wound
 Rapid bactericidal activity
 Persistent or residual skin 
activity, allowing more 
infrequent dosing
 Activity in the presence of  
body fluids and proteins in 
wound exudate
 Low likelihood of inducing 
bacterial resistance
 Some local skin penetration  
but no systemic absorption
 No associated toxic (to host 
tissue) or allergic reactions
 Acceptable cosmetic and 
aesthetic qualities
 Low cost
